
Design Therapeutics rose 29.0% from $7.34 to $9.47, ahead of the S&P 500's +10.2%. Its worst day was May 18 (−25.5%), and its low came Nov 19 at $7.34.
Nov 19, 2025 – Nov 18, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Design Therapeutics shares rose 11.9%, while the S&P 500 fell 0.3%.
+11.9% · S&P 500 −0.3%
Design Therapeutics shares rose 11.2%, while the S&P 500 rose 0.5%.
Story events cover the past 12 months · Times ET
+11.2% · S&P 500 +0.5%
EPS of $-0.27 beat the $-0.36 estimate on $0.00 revenue.
−3.7% · S&P 500 −0.2%
Design Therapeutics shares rose 11.6%, while the S&P 500 rose 0.5%.
+11.6% · S&P 500 +0.5%
EPS of $-0.29 beat the $-0.34 estimate on $0.00 revenue.
+23.3%, the year's best day · S&P 500 0.0%
Design Therapeutics shares fell 25.5%, while the S&P 500 fell 0.1%.
−25.5%, the year's worst day, on 8M shares, the year's heaviest volume · S&P 500 −0.1%
Design Therapeutics shares rose 11.3%, while the S&P 500 fell 1.5%.
+11.3% · S&P 500 −1.5%
EPS of $-0.32 beat the $-0.35 estimate on $0.00 revenue.
+4.8% · S&P 500 +1.4%
Design Therapeutics closed at its highest level of the year, 117.2% above where the year started.
+4.4% · S&P 500 +0.2%
EPS of $-0.32 beat the $-0.35 estimate on $0.00 revenue.
−9.0% · S&P 500 −4.4%
Where it ended: a close of $9.47 on Nov 18, 2026. Up next: Q4 2026 earnings on Mar 8, 2027 (EPS est. $-0.43).
Nothing in the past 12 months.
All DSGN dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for DSGN and SPY from Benzinga historical bars. Not investment advice.